|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO EXP |
[FABP1 protein affects the transport of Dronabinol] which affects the abundance of 11-hydroxy-delta(9)-tetrahydrocannabinol 11-hydroxy-delta(9)-tetrahydrocannabinol affects the folding of and results in increased stability of FABP1 protein; 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein] 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] |
CTD |
PMID:30232874 PMID:31110286 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
multiple interactions |
EXP |
11-hydroxy-delta(9)-tetrahydrocannabinol binds to and results in increased activity of TRPV2 protein |
CTD |
PMID:18550765 |
|
NCBI chr10:48,903,540...48,925,036
Ensembl chr10:48,903,540...48,925,030
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:146,630,298...146,690,375
Ensembl chr 3:146,630,299...146,690,375
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:18,647,903...18,695,133
Ensembl chr15:18,647,844...18,695,133
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:132,996,646...133,002,201
Ensembl chr 8:132,996,649...133,002,201
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:30102254 PMID:31024316 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:11,490,852...11,499,287
Ensembl chr 7:11,490,852...11,499,282
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:30301768 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:132,702,443...132,726,848
Ensembl chr 6:132,702,448...132,727,046
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of anandamide |
CTD |
PMID:30102254 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity increases response to substance decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:29730318 PMID:31024316 PMID:31199905 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
decreases abundance |
ISO |
CRH protein results in decreased abundance of anandamide |
CTD |
PMID:26821211 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 PMID:29441458 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:25,161,130...25,168,182
Ensembl chr12:25,161,130...25,168,182
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:29787777 PMID:31121907 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
increases degradation affects expression multiple interactions |
ISO |
FAAH results in increased degradation of anandamide anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide |
CTD |
PMID:16131814 PMID:16886060 PMID:20702753 PMID:31121907 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects abundance affects binding |
EXP ISO |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 PMID:30232874 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Lep |
leptin |
decreases abundance multiple interactions decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 PMID:29967158 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
anandamide results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein |
CTD |
PMID:27151562 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abl2 |
ABL proto-oncogene 2, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of ABL2 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr13:74,154,533...74,333,244
Ensembl chr13:74,154,835...74,333,244
|
|
G |
Actn1 |
actinin, alpha 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ACTN1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of ADCY5 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ADCY9 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:11,392,698...11,515,406
Ensembl chr10:11,392,625...11,512,600
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
increases expression |
ISO |
Cannabidiol results in increased expression of AGTRAP mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
|
|
G |
Aicda |
activation-induced cytidine deaminase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of AICDA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of AICDA mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 4:155,359,909...155,371,104
Ensembl chr 4:155,359,921...155,369,671
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
ISO |
Cannabidiol results in increased expression of AKR1B7 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation affects expression multiple interactions increases expression |
ISO |
Cannabidiol results in decreased phosphorylation of AKT1 protein Cannabidiol affects the expression of AKT1 protein tanespimycin affects the reaction [Cannabidiol affects the expression of AKT1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of AKT1 protein] Cannabidiol results in increased expression of AKT1 mRNA |
CTD |
PMID:26504004 PMID:28392768 PMID:33019509 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Angptl6 |
angiopoietin-like 6 |
increases expression |
ISO |
Cannabidiol results in increased expression of ANGPTL6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:21,895,523...21,902,002
Ensembl chr 8:21,895,524...21,901,829
|
|
G |
Apc2 |
APC regulator of WNT signaling pathway 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of APC2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:12,258,468...12,280,459
Ensembl chr 7:12,258,468...12,275,609
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [APP gene mutant form co-treated with PSEN1 gene mutant form] |
CTD |
PMID:21350020 PMID:27567873 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
Cannabidiol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of AQP9 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of AQP9 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Arpc1a |
actin related protein 2/3 complex, subunit 1A |
affects methylation |
EXP |
Cannabidiol affects the methylation of ARPC1A gene |
CTD |
PMID:30521419 |
|
NCBI chr12:11,272,609...11,294,084
Ensembl chr12:11,272,609...11,294,058
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ARRB2 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of ASB2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr 6:127,212,325...127,248,451
Ensembl chr 6:127,212,273...127,248,372
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of ASNS mRNA Cannabidiol results in increased expression of ASNS mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of ATF3 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of ATF3 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA] |
CTD |
PMID:21542829 PMID:26504004 PMID:27256343 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATF4 mRNA |
CTD |
PMID:21542829 PMID:33019509 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATF5 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG12 mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr18:40,721,799...40,732,143
Ensembl chr18:40,721,800...40,732,126
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG4B mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of ATP2A3 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:59,528,849...59,560,440
Ensembl chr10:59,529,785...59,560,433
|
|
G |
Avil |
advillin |
increases expression |
ISO |
Cannabidiol results in increased expression of AVIL mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:70,292,565...70,310,588
Ensembl chr 7:70,292,565...70,310,588
|
|
G |
Axin2 |
axin 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of AXIN2 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Cannabidiol results in increased expression of AXL mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of BACH1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of BACH1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] |
CTD |
PMID:27430346 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Cannabidiol results in increased expression of BDNF protein |
CTD |
PMID:19939866 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of BECN1 mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of BMP6 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
affects methylation |
EXP |
Cannabidiol affects the methylation of BMP7 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
|
|
G |
Bsg |
basigin (Ok blood group) |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of BSG mRNA [Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA; Cannabidiol promotes the reaction [Dronabinol results in decreased expression of BSG mRNA]; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA]; Dronabinol promotes the reaction [Cannabidiol results in decreased expression of BSG mRNA] |
CTD |
PMID:27769052 |
|
NCBI chr 7:12,875,536...12,882,753
Ensembl chr 7:12,875,537...12,882,753
|
|
G |
Btla |
B and T lymphocyte associated |
multiple interactions increases expression |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA] Cannabidiol results in increased expression of BTLA mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:60,523,692...60,547,234
Ensembl chr11:60,524,917...60,547,201
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
Cannabidiol results in decreased expression of C1QA mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1A gene |
CTD |
PMID:30521419 |
|
NCBI chr19:25,453,236...25,749,550
Ensembl chr19:25,526,751...25,749,550
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1G gene |
CTD |
PMID:30521419 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA1I gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:121,521,787...121,619,300
Ensembl chr 7:121,511,097...121,619,283
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA2D1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CACNA2D2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:116,154,661...116,285,643
Ensembl chr 8:116,154,736...116,284,985
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:33019509 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression |
ISO |
Cannabidiol results in increased expression of CARS mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:27430346 PMID:32708634 PMID:32733202 PMID:33076330 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of CASP4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CASP8 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CAT protein |
CTD |
PMID:32752303 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCL2 mRNA Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA] |
CTD |
PMID:19910459 PMID:21542829 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCL22 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCL6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCL7 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCND1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CCNE1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CCNE2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCNE2 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Cannabidiol results in increased expression of CD274 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CD69 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CDC25A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CDC25A mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CDC6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
affects expression multiple interactions |
ISO |
Cannabidiol affects the expression of CDK1 protein tanespimycin affects the reaction [Cannabidiol affects the expression of CDK1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of CDK1 protein] |
CTD |
PMID:26504004 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CDKN1A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CDKN1A mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression decreases expression |
ISO EXP |
Cannabidiol results in increased expression of CDKN2A mRNA Cannabidiol results in decreased expression of CDKN2A mRNA |
CTD |
PMID:21542829 PMID:32553926 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
ISO |
Cannabidiol results in increased expression of CDKN2B mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CEBPB mRNA Cannabidiol results in increased expression of CEBPB mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
Cannabidiol results in increased expression of CFLAR mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of CHAC1 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of CHAC1 mRNA |
CTD |
PMID:21542829 PMID:26504004 |
|
NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of CHD2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of CHRNA2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chst10 |
carbohydrate sulfotransferase 10 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CHST10 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:45,528,928...45,559,365
Ensembl chr 9:45,528,928...45,559,140
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
ISO |
Cannabidiol results in increased expression of CISH mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 8:116,054,547...116,059,494
Ensembl chr 8:116,054,465...116,060,723
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
increases expression |
ISO |
Cannabidiol results in increased expression of CLEC4E mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:156,271,087...156,276,243
Ensembl chr 4:156,270,920...156,276,304
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CLOCK mRNA |
CTD |
PMID:33019509 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Cmpk2 |
cytidine/uridine monophosphate kinase 2 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 6:45,683,242...45,694,824
Ensembl chr 6:45,683,234...45,694,822
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance |
ISO EXP |
CNR1 polymorphism affects the susceptibility to [Dronabinol co-treated with Cannabidiol]; CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]] [1,3-dimethoxy-5-methyl-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)benzene co-treated with CNR1 protein] affects the susceptibility to Cannabidiol CNR1 protein affects the susceptibility to Cannabidiol |
CTD |
PMID:20668920 PMID:30550613 PMID:31013550 PMID:31202911 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects expression |
ISO |
CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol affects the expression of CNR2 mRNA |
CTD |
PMID:20668920 PMID:32733202 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
increases expression |
ISO |
Cannabidiol results in increased expression of COL4A1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Cannabidiol results in increased expression of COX6A2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cpd |
carboxypeptidase D |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CPD mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:63,325,764...63,389,811
Ensembl chr10:63,325,199...63,389,817
|
|
G |
Cpeb1 |
cytoplasmic polyadenylation element binding protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of CPEB1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:143,171,457...143,278,485
Ensembl chr 1:143,171,264...143,278,485
|
|
G |
Crb1 |
crumbs cell polarity complex component 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of CRB1 gene |
CTD |
PMID:30521419 |
|
NCBI chr13:56,270,519...56,462,893
Ensembl chr13:56,270,781...56,462,834
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation decreases expression multiple interactions |
ISO |
Cannabidiol results in increased phosphorylation of CREB1 protein Cannabidiol results in decreased expression of CREB1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:28601556 PMID:33019509 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crem |
cAMP responsive element modulator |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CREM mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
affects methylation |
EXP |
Cannabidiol affects the methylation of CSF2RA gene |
CTD |
PMID:30521419 |
|
NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
affects methylation |
EXP |
Cannabidiol affects the methylation of CSNK1E gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:120,651,976...120,675,559
Ensembl chr 7:120,651,881...120,672,359
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CSRNP1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:128,659,883...128,673,339
Ensembl chr 8:128,659,868...128,672,284
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of CTH mRNA Cannabidiol results in increased expression of CTH mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctsg |
cathepsin G |
increases expression |
ISO |
Cannabidiol results in increased expression of CTSG mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:35,107,333...35,113,678
Ensembl chr15:35,111,091...35,113,678
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:32244040 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CXCL14 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCR1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 9:81,466,430...81,469,299
Ensembl chr 9:81,466,332...81,469,274
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CXCR4 mRNA [Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA] Cannabidiol results in increased expression of CXCR4 mRNA |
CTD |
PMID:27769052 PMID:30742662 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Cannabidiol results in decreased activity of CYP19A1 protein Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP1A1 protein |
CTD |
PMID:24667653 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP1A2 protein |
CTD |
PMID:24667653 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2B10 |
CTD |
PMID:8043019 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2B6 protein |
CTD |
PMID:24667653 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2C19 protein |
CTD |
PMID:24667653 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP2D6 protein |
CTD |
PMID:24667653 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP3A4 protein |
CTD |
PMID:24667653 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases activity |
ISO |
Cannabidiol results in decreased activity of CYP3A5 protein |
CTD |
PMID:24667653 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyrib |
CYFIP related Rac1 interactor B |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYRIB mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:104,514,566...104,641,875
Ensembl chr 7:104,516,391...104,556,419
|
|
G |
Cytip |
cytohesin 1 interacting protein |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CYTIP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:44,150,494...44,225,723
Ensembl chr 3:44,150,992...44,177,689
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of DAPK3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Dct |
dopachrome tautomerase |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DCT mRNA; Cannabidiol results in increased expression of DCT protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr15:103,208,174...103,245,033
Ensembl chr15:103,208,258...103,244,494
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DDIT3 mRNA Cannabidiol results in increased expression of DDIT3 mRNA; Cannabidiol results in increased expression of DDIT3 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of DDIT3 mRNA [Bilirubin co-treated with Rotenone] promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA] |
CTD |
PMID:21542829 PMID:26504004 PMID:29441458 PMID:32033040 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of DDIT4 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA |
CTD |
PMID:21542829 PMID:26504004 PMID:30742662 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DDR1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr20:3,553,430...3,574,959
Ensembl chr20:3,552,929...3,575,780
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of DGAT1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
affects methylation multiple interactions |
EXP ISO |
Cannabidiol affects the methylation of DLG4 gene [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein] |
CTD |
PMID:27567873 PMID:30521419 |
|
NCBI chr10:56,625,845...56,655,543
Ensembl chr10:56,627,411...56,653,599
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DLGAP1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 9:118,277,046...119,159,807
Ensembl chr 9:118,586,179...119,158,196
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of DLL1 mRNA] Cannabidiol results in increased expression of DLL1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:57,318,621...57,326,732
Ensembl chr 1:57,318,708...57,327,379
|
|
G |
Dmd |
dystrophin |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG12 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG4B mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of BECN1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ULK1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6RA mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TGFB1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF protein] |
CTD |
PMID:30074247 |
|
NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DNAJB1 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of DNAJB4 mRNA Cannabidiol results in increased expression of DNAJB4 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 2:257,394,692...257,425,344
Ensembl chr 2:257,394,818...257,425,242
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of DNAJB9 mRNA Cannabidiol results in increased expression of DNAJB9 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 6:64,165,913...64,170,122
Ensembl chr 6:64,165,913...64,170,151
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
increases expression |
ISO |
Cannabidiol results in increased expression of DNMT3L mRNA |
CTD |
PMID:21542829 |
|
NCBI chr20:11,344,513...11,359,090
Ensembl chr20:11,344,514...11,359,090
|
|
G |
Dok2 |
docking protein 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DOK2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:52,449,884...52,455,414
Ensembl chr15:52,451,161...52,456,409
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of DRD2 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of DUSP1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
E2f2 |
E2F transcription factor 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of E2F2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
|
|
G |
E2f5 |
E2F transcription factor 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of E2F5 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:88,350,764...88,366,913
Ensembl chr 2:88,351,361...88,366,115
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA; Pertussis Toxin inhibits the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of EGR1 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of EGR1 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EIF2AK3 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of EIF5A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of ENO2 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of EPHX1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ERN1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
increases expression |
ISO |
Cannabidiol results in increased expression of ETS2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:36,075,709...36,092,495
Ensembl chr11:36,075,709...36,092,495
|
|
G |
Ezr |
ezrin |
affects methylation |
EXP |
Cannabidiol affects the methylation of EZR gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Cannabidiol results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] |
CTD |
PMID:31110286 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Cannabidiol results in increased expression of FAS mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of FBXO32 mRNA Cannabidiol results in increased expression of FBXO32 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of FDPS mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
|
|
G |
Fgf12 |
fibroblast growth factor 12 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGF12 gene |
CTD |
PMID:30521419 |
|
NCBI chr11:75,606,360...76,171,078
Ensembl chr11:75,905,443...76,168,989
|
|
G |
Fgf14 |
fibroblast growth factor 14 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGF14 gene |
CTD |
PMID:30521419 |
|
NCBI chr15:110,382,274...111,077,027
Ensembl chr15:110,385,217...110,612,681
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGFR2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FGFR4 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of FOS mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of FOS mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Cannabidiol results in increased expression of FOSB mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Fzd9 |
frizzled class receptor 9 |
affects methylation |
EXP |
Cannabidiol affects the methylation of FZD9 gene |
CTD |
PMID:30521419 |
|
NCBI chr12:24,473,981...24,476,295
Ensembl chr12:24,473,981...24,476,295
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein] |
CTD |
PMID:27567873 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [Poly I-C results in decreased expression of GAD1 protein] |
CTD |
PMID:31202911 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of GADD45A mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of GADD45A mRNA |
CTD |
PMID:21542829 PMID:26504004 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of GAS1 mRNA Cannabidiol results in increased expression of GAS1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Cannabidiol results in increased expression of GCLM mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of GDF15 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of GDF15 mRNA |
CTD |
PMID:21542829 PMID:26504004 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gdf6 |
growth differentiation factor 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GDF6 gene |
CTD |
PMID:30521419 |
|
NCBI chr 5:23,056,345...23,072,666
Ensembl chr 5:23,056,347...23,074,599
|
|
G |
Gfod1 |
glucose-fructose oxidoreductase domain containing 1 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GFOD1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792
|
|
G |
Gli1 |
GLI family zinc finger 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GLI1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:70,620,794...70,633,171
Ensembl chr 7:70,620,766...70,630,338
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
increases expression |
ISO |
Cannabidiol results in increased expression of GNAI2 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
|
|
G |
Gnal |
G protein subunit alpha L |
decreases expression |
ISO |
Cannabidiol results in decreased expression of GNAL mRNA |
CTD |
PMID:33019509 |
|
NCBI chr18:62,805,406...62,946,133
Ensembl chr18:62,805,410...62,944,630
|
|
G |
Gnb2 |
G protein subunit beta 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GNB2 gene |
CTD |
PMID:30521419 |
|
NCBI chr12:22,229,079...22,234,096
Ensembl chr12:22,229,079...22,234,096
|
|
G |
Gnb4 |
G protein subunit beta 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of GNB4 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 2:118,978,965...119,007,877
Ensembl chr 2:118,978,973...119,007,835
|
|
G |
Gng7 |
G protein subunit gamma 7 |
affects methylation |
EXP |
Cannabidiol affects the methylation of GNG7 gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:11,565,740...11,629,519
Ensembl chr 7:11,582,984...11,628,929
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
Cannabidiol results in increased expression of GPNMB mRNA |
CTD |
PMID:27256343 |
|
NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of GPR183 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:108,364,701...108,376,221
Ensembl chr15:108,364,701...108,376,221
|
|
G |
Gpr83 |
G protein-coupled receptor 83 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of GPR83 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:13,365,583...13,376,071
Ensembl chr 8:13,365,583...13,376,070
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of GPT2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:22,599,003...22,633,529
Ensembl chr19:22,590,881...22,632,071
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein] |
CTD |
PMID:27567873 |
|
NCBI chr 2:179,584,302...179,704,629
Ensembl chr 2:179,584,308...179,704,629
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
ISO |
Cannabidiol results in decreased activity of GSR protein |
CTD |
PMID:18929579 PMID:32752303 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of GSTM1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
Cannabidiol results in increased expression of H1F2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:43,638,938...43,640,445
Ensembl chr17:43,639,749...43,640,387
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
Cannabidiol promotes the reaction [Dronabinol results in increased expression of H2AX protein modified form]; Dronabinol promotes the reaction [Cannabidiol results in increased expression of H2AX protein modified form] |
CTD |
PMID:27769052 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hap1 |
huntingtin-associated protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of HAP1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:88,257,975...88,266,210
Ensembl chr10:88,257,976...88,266,210
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of HBP1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of HERPUD1 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of HERPUD1 mRNA |
CTD |
PMID:21542829 PMID:26504004 |
|
NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
|
|
G |
Hes2 |
hes family bHLH transcription factor 2 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of HES2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of HES2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:169,338,097...169,339,142
Ensembl chr 5:169,338,097...169,339,142
|
|
G |
Hgf |
hepatocyte growth factor |
affects methylation |
EXP |
Cannabidiol affects the methylation of HGF gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
increases expression |
ISO |
Cannabidiol results in increased expression of H2AC6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:43,627,237...43,627,629
Ensembl chr17:43,627,237...43,627,629
|
|
G |
Hist1h2ail1 |
histone cluster 1 H2a family member I like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of H3C6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:43,814,773...43,815,183
Ensembl chr17:43,814,773...43,815,183 Ensembl chr17:43,814,773...43,815,183
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
increases expression |
ISO |
Cannabidiol results in increased expression of H2BC21 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:198,360,837...198,363,399
Ensembl chr 2:198,360,998...198,361,378
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions affects response to substance |
ISO |
Cannabidiol results in increased expression of HMOX1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of HMOX1 mRNA; [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of HMOX1 mRNA] Cannabidiol results in increased expression of HMOX1 mRNA; Cannabidiol results in increased expression of HMOX1 protein HMOX1 protein affects the susceptibility to Cannabidiol [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; [Dronabinol co-treated with Cannabidiol] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Cannabidiol results in increased expression of HMOX1 protein]; iodopravadoline promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]; tin protoporphyrin IX promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein] |
CTD |
PMID:21542829 PMID:26504004 PMID:30349652 PMID:30742662 PMID:32033040 PMID:32708634 PMID:33076330 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf1a |
HNF1 homeobox A |
affects methylation |
EXP |
Cannabidiol affects the methylation of HNF1A gene |
CTD |
PMID:30521419 |
|
NCBI chr12:47,407,811...47,433,342
Ensembl chr12:47,407,811...47,433,342
|
|
G |
Hp |
haptoglobin |
increases expression |
ISO |
Cannabidiol results in increased expression of HP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:42,096,255...42,100,805
Ensembl chr19:42,097,995...42,100,804
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
ISO |
Cannabidiol results in increased expression of HSPA1A mRNA |
CTD |
PMID:26504004 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of HSPA1B mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of HSPA1B mRNA |
CTD |
PMID:26504004 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA; Bilirubin inhibits the reaction [[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA] |
CTD |
PMID:32033040 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of HTATIP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; AM 251 inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; capsazepine inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; ICAM1 mutant form inhibits the reaction [Cannabidiol results in increased expression of TIMP1 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA] Cannabidiol results in increased expression of ICAM1 mRNA; Cannabidiol results in increased expression of ICAM1 protein |
CTD |
PMID:22198381 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression affects response to substance |
ISO |
Cannabidiol results in decreased expression of ID1 mRNA; Cannabidiol results in decreased expression of ID1 protein ID1 protein affects the susceptibility to Cannabidiol |
CTD |
PMID:21542829 PMID:24910342 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
AM 281 promotes the reaction [Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]]; Cannabidiol inhibits the reaction [[Plant Preparations results in increased activity of IDO1 protein] which results in increased abundance of Neopterin]; Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]; Cannabidiol inhibits the reaction [Plant Preparations results in increased expression of IDO1 mRNA]; iodopravadoline promotes the reaction [Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]] |
CTD |
PMID:19167098 |
|
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IER3 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IFNB1 protein] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] Cannabidiol results in increased expression of IFNB1 mRNA |
CTD |
PMID:19910459 PMID:21542829 PMID:30742662 PMID:32244040 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol affects the reaction [Plant Preparations results in increased secretion of IFNG protein]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol inhibits the reaction [Plant Preparations results in increased expression of IFNG mRNA]; Cannabidiol promotes the reaction [Dronabinol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]]; Dronabinol promotes the reaction [Cannabidiol inhibits the reaction [IFNG results in increased expression of PSMB8 mRNA]] |
CTD |
PMID:19167098 PMID:27769052 PMID:31054246 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IFNGR1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 1:15,062,380...15,080,815
Ensembl chr 1:15,062,432...15,080,907
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:31953017 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of IGFBP4 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA] |
CTD |
PMID:21542829 PMID:27256343 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL12A mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL1B protein] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] Cannabidiol results in decreased expression of IL1B mRNA |
CTD |
PMID:19910459 PMID:21492165 PMID:21542829 PMID:27256343 PMID:27430346 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of IL2 protein |
CTD |
PMID:11809870 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL3 protein] |
CTD |
PMID:27256343 |
|
NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IL6 mRNA; [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]; Rotenone inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:19910459 PMID:21350020 PMID:21492165 PMID:27430346 PMID:30074247 PMID:30742662 PMID:32033040 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of IL6RA mRNA Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6RA mRNA] |
CTD |
PMID:30074247 PMID:30742662 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
decreases expression |
ISO |
Cannabidiol results in decreased expression of INPP5D mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 9:94,745,220...94,850,778
Ensembl chr 9:94,745,217...94,850,771
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of IRAK1 protein] |
CTD |
PMID:19910459 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IRAK3 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 7:64,922,830...64,982,224
Ensembl chr 7:64,923,615...64,982,281
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein] |
CTD |
PMID:32244040 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions increases expression |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of IRF4 mRNA] Cannabidiol results in increased expression of IRF4 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Itgb3 |
integrin subunit beta 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of ITGB3 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:92,667,869...92,783,413
Ensembl chr10:92,667,869...92,783,410
|
|
G |
Jak3 |
Janus kinase 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of JAK3 gene |
CTD |
PMID:30521419 |
|
NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
|
|
G |
Jaml |
junction adhesion molecule like |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of JAML mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 8:49,378,644...49,408,894
Ensembl chr 8:49,378,644...49,410,088
|
|
G |
Jdp2 |
Jun dimerization protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of JDP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 6:109,464,910...109,505,591
Ensembl chr 6:109,466,060...109,505,161
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of KCTD12 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr15:87,384,632...87,390,627
|
|
G |
Klf4 |
Kruppel like factor 4 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of KLF4 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of KLF4 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases expression |
EXP |
Cannabidiol results in decreased expression of KRAS mRNA |
CTD |
PMID:32553926 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of LAMC1 gene |
CTD |
PMID:30521419 |
|
NCBI chr13:70,656,727...70,783,515
Ensembl chr13:70,658,707...70,783,515
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of LCN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Limk2 |
LIM domain kinase 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of LIMK2 gene |
CTD |
PMID:30521419 |
|
NCBI chr14:83,564,048...83,641,996
Ensembl chr14:83,573,928...83,641,892
|
|
G |
Llgl1 |
LLGL scribble cell polarity complex component 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of LLGL1 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:46,940,873...46,955,524
Ensembl chr10:46,940,965...46,954,674
|
|
G |
LOC102553180 |
protocadherin alpha-1-like |
increases expression |
ISO |
Cannabidiol results in increased expression of PCDHA1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr18:29,824,891...29,839,850
|
|
G |
LOC103689977 |
caspase-6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CASP6 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 2:230,186,170...230,198,555
Ensembl chr 2:230,186,198...230,198,555
|
|
G |
LOC686035 |
similar to heat shock 70kDa protein 6 (HSP70B) |
increases expression |
ISO |
Cannabidiol results in increased expression of HSPA6 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr13:89,408,703...89,411,500
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of LPIN1 mRNA Cannabidiol results in increased expression of LPIN1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of LY86 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:28,104,535...28,191,447
Ensembl chr17:28,104,589...28,191,436
|
|
G |
Mafb |
MAF bZIP transcription factor B |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of MAFB mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MAFB mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:156,338,993...156,340,913
Ensembl chr 3:156,339,004...156,340,913
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of MAP2K1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
affects methylation |
EXP |
Cannabidiol affects the methylation of MAP2K6 gene |
CTD |
PMID:30521419 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions affects expression |
ISO |
Cannabidiol results in increased phosphorylation of MAPK1 protein tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of MAPK1 protein] |
CTD |
PMID:26504004 PMID:28601556 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
EXP |
Cannabidiol results in decreased expression of MAPK14 mRNA |
CTD |
PMID:32553926 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions affects expression |
ISO |
Cannabidiol results in increased phosphorylation of MAPK3 protein tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK3 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of MAPK3 protein] |
CTD |
PMID:26504004 PMID:28601556 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
affects methylation |
EXP |
Cannabidiol affects the methylation of MAPT gene |
CTD |
PMID:30521419 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MAT2A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:100,297,478...100,303,047
Ensembl chr 4:100,296,075...100,303,080
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MDM2 mRNA Cannabidiol results in increased expression of MDM2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mecom |
MDS1 and EVI1 complex locus |
affects methylation |
EXP |
Cannabidiol affects the methylation of MECOM gene |
CTD |
PMID:30521419 |
|
NCBI chr 2:117,396,084...117,993,604
Ensembl chr 2:117,396,007...117,454,769
|
|
G |
Mef2b |
myocyte enhancer factor 2B |
increases expression |
ISO |
Cannabidiol results in increased expression of MEF2B mRNA |
CTD |
PMID:21542829 |
|
NCBI chr16:21,001,204...21,017,651
Ensembl chr16:21,001,206...21,017,163
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MEF2C mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:11,658,534...11,822,788
Ensembl chr 2:11,658,568...11,822,787
|
|
G |
Mir145 |
microRNA 145 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR145A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions decreases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR146 mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MIR146 mRNA] Cannabidiol results in decreased expression of MIR146 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MIR155 mRNA] |
CTD |
PMID:30742662 |
|
NCBI chr11:24,176,603...24,176,667
Ensembl chr11:24,176,603...24,176,667
|
|
G |
Mir181b1 |
microRNA 181b-1 |
increases expression |
ISO |
Cannabidiol results in increased expression of MIR181B-1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr13:54,952,903...54,953,012
Ensembl chr13:54,952,903...54,953,012
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR21A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mir221 |
microRNA 221 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR221 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr X:3,684,480...3,684,588
Ensembl chr X:3,684,480...3,684,588
|
|
G |
Mir222 |
microRNA 222 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR222 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr X:3,683,919...3,684,021
Ensembl chr X:3,683,919...3,684,021
|
|
G |
Mir25 |
microRNA 25 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MIR25 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr12:19,307,340...19,307,423
Ensembl chr12:19,307,340...19,307,423
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions increases expression |
ISO |
[Cannabidiol co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MIR34A mRNA Cannabidiol results in increased expression of MIR34A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mir449a |
microRNA 449a |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of MIR449A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR449A mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:44,897,601...44,897,691
Ensembl chr 2:44,897,601...44,897,691
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of MITF mRNA; Cannabidiol results in increased expression of MITF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr 4:130,172,484...130,425,496
Ensembl chr 4:130,172,727...130,425,532
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of MKI67 protein |
CTD |
PMID:24910342 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp23 |
matrix metallopeptidase 23 |
increases expression |
ISO |
Cannabidiol results in increased expression of MMP23 mRNA |
CTD |
PMID:21542829 PMID:22178458 |
|
NCBI chr 5:173,078,811...173,082,834
Ensembl chr 5:173,078,590...173,081,839
|
|
G |
Mog |
myelin oligodendrocyte glycoprotein |
multiple interactions |
ISO |
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CREM mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CSRNP1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCR1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of DGAT1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of FDPS mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of GPR83 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IER3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IFNGR1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL12A mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of JAML mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of NR4A3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of SPHK1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF18 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF9 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF11 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF14 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TUBB2B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of VPS37B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of XCL1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL3 protein]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CD69 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GBP11 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GFOD1 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of IRF4 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of MX2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of PPIC mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of RSAD2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TAGAP mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TNFSF8 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TRIM30A mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr20:2,003,871...2,014,284
Ensembl chr20:2,004,052...2,014,286
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MR1 mRNA Cannabidiol results in increased expression of MR1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of MT1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
Cannabidiol results in increased expression of MT2 mRNA |
CTD |
PMID:21542829 PMID:22178458 PMID:27256343 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of MX2 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr11:38,035,306...38,066,185
Ensembl chr11:38,035,450...38,059,950
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
affects methylation |
EXP |
Cannabidiol affects the methylation of MYC gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myh6 |
myosin heavy chain 6 |
increases expression |
ISO |
Cannabidiol results in increased expression of MYHC mRNA |
CTD |
PMID:30074247 |
|
NCBI chr15:33,605,653...33,629,730
Ensembl chr15:33,605,654...33,629,699
|
|
G |
Myog |
myogenin |
multiple interactions increases expression |
ISO |
iodoresiniferatoxin inhibits the reaction [Cannabidiol results in increased expression of MYOG mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
|
|
G |
Nckap1l |
NCK associated protein 1 like |
affects methylation |
EXP |
Cannabidiol affects the methylation of NCKAP1L gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:145,068,239...145,113,507
Ensembl chr 7:145,068,286...145,113,507
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of NDRG1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of NDRG1 mRNA |
CTD |
PMID:21542829 PMID:22178458 PMID:30742662 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Neurl1 |
neuralized E3 ubiquitin protein ligase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NEURL1A mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:266,953,006...267,038,879
Ensembl chr 1:266,952,561...267,038,883
|
|
G |
Nfam1 |
NFAT activating protein with ITAM motif 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of NFAM1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:123,856,718...123,893,790
Ensembl chr 7:123,856,567...123,892,429
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
decreases expression multiple interactions |
ISO |
Cannabidiol results in decreased expression of NFATC2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of NFATC2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:165,241,750...165,374,644
Ensembl chr 3:165,245,238...165,360,292
|
|
G |
Nfe2l1 |
nuclear factor, erythroid 2-like 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NFE2L1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr10:84,686,762...84,699,313
Ensembl chr10:84,682,460...84,698,886
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of NFE2L2 protein NFE2L2 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein] |
CTD |
PMID:32708634 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
ISO |
Cannabidiol results in increased expression of NFIL3 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr17:12,261,102...12,276,316
Ensembl chr17:12,261,102...12,276,315
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NFKB1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbib |
NFKB inhibitor beta |
increases expression |
ISO |
Cannabidiol results in increased expression of NFKBIB mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Cannabidiol results in increased expression of NOS2 mRNA Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of NOS2 protein] |
CTD |
PMID:27430346 PMID:30074247 PMID:30742662 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of NQO1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of NR4A3 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:63,781,801...63,822,890
Ensembl chr 5:63,781,801...63,821,637
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of NTRK2 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Cannabidiol results in increased expression of NUPR1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [naltrindole binds to and results in decreased activity of OPRD1 protein] |
CTD |
PMID:16489449 |
|
NCBI chr 5:150,288,126...150,323,063
Ensembl chr 5:150,288,126...150,323,063
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
EXP |
Cannabidiol promotes the reaction [Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]] |
CTD |
PMID:16489449 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Cannabidiol results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Parp4 |
poly (ADP-ribose) polymerase family, member 4 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of PARP4 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr15:36,809,362...36,911,167
|
|
G |
Pax8 |
paired box 8 |
affects methylation |
EXP |
Cannabidiol affects the methylation of PAX8 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:1,527,316...1,586,019
Ensembl chr 3:1,527,279...1,584,946
|
|
G |
Pcdha1 |
protocadherin alpha 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of PCDHA1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr18:29,951,094...30,215,896
|
|
G |
Pcdha11 |
protocadherin alpha 11 |
increases expression |
ISO |
Cannabidiol results in increased expression of PCDHA11 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr18:30,017,918...30,215,896
Ensembl chr18:29,987,206...30,215,897
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
increases expression |
EXP |
Cannabidiol results in increased expression of PDX1 protein |
CTD |
PMID:32553926 |
|
NCBI chr12:9,496,044...9,501,211
Ensembl chr12:9,496,044...9,501,213
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of PENK mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 5:17,056,412...17,061,762
Ensembl chr 5:17,056,419...17,061,837
|
|
G |
Pfn2 |
profilin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PFN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:147,953,858...147,959,692
Ensembl chr 2:147,955,196...148,050,438
|
|
G |
Pip5k1c |
phosphatidylinositol-4-phosphate 5-kinase type 1 gamma |
affects methylation |
EXP |
Cannabidiol affects the methylation of PIP5K1C gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:11,267,207...11,294,291
Ensembl chr 7:11,267,218...11,294,249
|
|
G |
Pitpnm2 |
phosphatidylinositol transfer protein, membrane-associated 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PITPNM2 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr12:37,805,332...37,903,856
Ensembl chr12:37,805,332...37,903,855
|
|
G |
Pld1 |
phospholipase D1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of PLD1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 2:113,651,967...113,849,403
Ensembl chr 2:113,652,348...113,849,403
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PLIN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:104,984,413...105,010,863
Ensembl chr 5:104,984,414...105,010,857
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of PLK2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
increases expression |
ISO |
Cannabidiol results in increased expression of PLPP3 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:124,690,214...124,765,499
Ensembl chr 5:124,690,214...124,765,498
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of PMAIP1 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Polr1g |
RNA polymerase I subunit G |
decreases expression |
ISO |
Cannabidiol results in decreased expression of CD3EAP mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:80,267,725...80,271,001
Ensembl chr 1:80,267,725...80,271,001
|
|
G |
Pomgnt2 |
protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) |
decreases expression |
ISO |
Cannabidiol results in decreased expression of POMGNT2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:130,615,482...130,631,144
Ensembl chr 8:130,615,711...130,617,833
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of POU5F1 gene |
CTD |
PMID:30521419 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects methylation |
EXP |
Cannabidiol affects the methylation of PPARD gene |
CTD |
PMID:30521419 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases expression multiple interactions affects binding |
ISO EXP |
Cannabidiol results in increased expression of PPARG mRNA Cannabidiol results in decreased expression of PPARG protein [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of PPARG mRNA Cannabidiol binds to PPARG protein Cannabidiol results in increased expression of and affects the localization of PPARG protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cannabidiol affects the localization of PPARG protein] |
CTD |
PMID:19285060 PMID:23220503 PMID:28853159 PMID:30742662 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppic |
peptidylprolyl isomerase C |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of PPIC mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr18:48,372,039...48,384,645
Ensembl chr18:48,372,041...48,384,645
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
affects methylation |
EXP |
Cannabidiol affects the methylation of PPP1CC gene |
CTD |
PMID:30521419 |
|
NCBI chr12:39,864,302...39,882,030
Ensembl chr12:39,864,295...39,882,030
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of PPP1R15A mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of PPP1R15A mRNA |
CTD |
PMID:21542829 PMID:26504004 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
increases expression |
ISO |
Cannabidiol results in increased expression of PPP1R3C mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 1:255,371,830...255,376,833
Ensembl chr 1:255,371,810...255,376,833
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha |
decreases expression |
ISO |
Cannabidiol results in decreased expression of PPP3R1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr14:100,311,224...100,360,879
Ensembl chr14:100,311,173...100,360,879
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
affects methylation |
EXP |
Cannabidiol affects the methylation of PRKACA gene |
CTD |
PMID:30521419 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prkca |
protein kinase C, alpha |
increases expression |
ISO |
Cannabidiol results in increased expression of PRKCA mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkcb |
protein kinase C, beta |
decreases expression |
ISO |
Cannabidiol results in decreased expression of PRKCB mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein] |
CTD |
PMID:31154070 PMID:31953017 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
multiple interactions increases expression |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of PSAT1 mRNA Cannabidiol results in increased expression of PSAT1 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 1:233,124,089...233,145,941
Ensembl chr 1:233,124,092...233,145,941
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [APP gene mutant form co-treated with PSEN1 gene mutant form] |
CTD |
PMID:27567873 |
|
NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
|
|
G |
Psmb8 |
proteasome 20S subunit beta 8 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol promotes the reaction [Dronabinol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]]; Dronabinol promotes the reaction [Cannabidiol inhibits the reaction [IFNG results in increased expression of PSMB8 mRNA]] |
CTD |
PMID:27769052 |
|
NCBI chr20:3,990,809...3,993,772
Ensembl chr20:3,990,613...3,993,769
|
|
G |
Ptch1 |
patched 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of PTCH1 gene |
CTD |
PMID:30521419 |
|
NCBI chr17:1,032,242...1,085,885
Ensembl chr17:1,029,048...1,093,873
|
|
G |
Ptgir |
prostaglandin I2 receptor |
increases expression |
ISO |
Cannabidiol results in increased expression of PTGIR mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:78,833,449...78,835,832
Ensembl chr 1:78,833,157...78,837,623
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Cannabidiol results in increased expression of PTGS2 mRNA; Cannabidiol results in increased expression of PTGS2 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of PTGS2 mRNA Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of PTGS2 mRNA] |
CTD |
PMID:23220503 PMID:26504004 PMID:27430346 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptpn14 |
protein tyrosine phosphatase, non-receptor type 14 |
increases expression |
ISO |
Cannabidiol results in increased expression of PTPN14 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr13:108,689,916...108,841,593
Ensembl chr13:108,696,336...108,841,511
|
|
G |
Ptprj |
protein tyrosine phosphatase, receptor type, J |
decreases expression |
ISO |
Cannabidiol results in decreased expression of PTPRJ mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:79,233,519...79,390,956
Ensembl chr 3:79,233,525...79,390,956
|
|
G |
Pvalb |
parvalbumin |
multiple interactions increases expression |
EXP |
[Poly I-C co-treated with Cannabidiol] results in increased expression of PVALB protein Cannabidiol results in increased expression of PVALB protein |
CTD |
PMID:31202911 PMID:31326506 |
|
NCBI chr 7:119,428,657...119,443,674
Ensembl chr 7:119,429,019...119,441,487
|
|
G |
Rab3il1 |
RAB3A interacting protein-like 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of RAB3IL1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:226,077,182...226,084,830
Ensembl chr 1:226,077,120...226,084,830
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of RASGRP1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 3:108,984,029...109,044,420
Ensembl chr 3:108,984,029...109,044,420
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RELA mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] |
CTD |
PMID:19910459 PMID:30742662 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression |
ISO |
Cannabidiol results in increased expression of RELB mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Rin2 |
Ras and Rab interactor 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of RIN2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:139,871,330...140,087,679
Ensembl chr 3:139,894,331...140,087,678
|
|
G |
Rnd3 |
Rho family GTPase 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of RND3 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of RND3 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 3:36,643,374...36,660,727
Ensembl chr 3:36,642,587...36,660,758
|
|
G |
Rora |
RAR-related orphan receptor A |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RORA mRNA Cannabidiol results in increased expression of RORA mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 8:75,515,886...75,616,477
Ensembl chr 8:75,516,904...75,607,212
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Cannabidiol results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:28392768 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RSAD2 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of RSAD2 mRNA] Cannabidiol results in increased expression of RSAD2 mRNA |
CTD |
PMID:27256343 PMID:30742662 |
|
NCBI chr 6:45,655,947...45,669,083
Ensembl chr 6:45,655,954...45,669,148
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of S1PR1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 2:218,654,406...218,658,761
Ensembl chr 2:218,654,554...218,658,761
|
|
G |
Sars1 |
seryl-tRNA synthetase 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SARS mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 2:211,219,743...211,235,475
Ensembl chr 2:211,219,750...211,235,467
|
|
G |
Scin |
scinderin |
affects methylation |
EXP |
Cannabidiol affects the methylation of SCIN gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:59,975,375...60,055,075
Ensembl chr 6:59,976,003...60,054,279
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression increases response to substance decreases secretion multiple interactions |
ISO |
Cannabidiol results in decreased expression of SERPINE1 mRNA SERPINE1 protein results in increased susceptibility to Cannabidiol Cannabidiol results in decreased secretion of SERPINE1 protein CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]; CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]; TRPV1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] |
CTD |
PMID:20668920 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sesn2 |
sestrin 2 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of SESN2 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of SESN2 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Sfxn4 |
sideroflexin 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SFXN4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:282,213,610...282,236,851
Ensembl chr 1:282,213,675...282,235,974
|
|
G |
Shank1 |
SH3 and multiple ankyrin repeat domains 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SHANK1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 1:100,297,137...100,344,377
Ensembl chr 1:100,297,152...100,344,377
|
|
G |
Slc18a1 |
solute carrier family 18 member A1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC18A1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr16:22,358,646...22,395,183
Ensembl chr16:22,361,998...22,395,183
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC1A4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr14:104,582,884...104,612,417
Ensembl chr14:104,581,190...104,612,597
|
|
G |
Slc25a22 |
solute carrier family 25 member 22 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC25A22 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:214,410,388...214,418,236
Ensembl chr 1:214,410,417...214,414,897
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:5,567,729...5,575,144
Ensembl chr 3:5,568,321...5,575,136
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of SLC30A1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of SLC30A1 mRNA |
CTD |
PMID:21542829 PMID:22178458 PMID:27256343 PMID:30742662 |
|
NCBI chr13:110,677,810...110,681,683
Ensembl chr13:110,677,810...110,681,683
|
|
G |
Slc32a1 |
solute carrier family 32 member 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC32A1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 3:155,102,980...155,107,815
Ensembl chr 3:155,103,150...155,107,817
|
|
G |
Slc38a1 |
solute carrier family 38, member 1 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC38A1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 7:137,970,555...138,040,098
Ensembl chr 7:137,975,549...138,039,984
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC39A10 mRNA |
CTD |
PMID:21542829 PMID:22178458 |
|
NCBI chr 9:59,947,562...60,070,549
Ensembl chr 9:60,021,534...60,070,552
|
|
G |
Slc39a4 |
solute carrier family 39 member 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC39A4 mRNA |
CTD |
PMID:21542829 PMID:22178458 |
|
NCBI chr 7:117,675,718...117,682,586
Ensembl chr 7:117,675,720...117,680,004
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC3A2 mRNA |
CTD |
PMID:21542829 PMID:27256343 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC40A1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of SLC5A6 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 6:26,685,823...26,697,110
Ensembl chr 6:26,686,033...26,697,116
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
ISO |
Cannabidiol results in increased expression of SLC6A9 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:136,669,674...136,703,702
Ensembl chr 5:136,669,674...136,703,697
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of SLC7A11 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of SLC7A11 mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein] |
CTD |
PMID:27567873 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
G |
Sned1 |
sushi, nidogen and EGF-like domains 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SNED1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 9:100,380,487...100,439,125
Ensembl chr 9:100,380,515...100,437,056
|
|
G |
Soat2 |
sterol O-acyltransferase 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of SOAT2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:143,754,892...143,767,989
Ensembl chr 7:143,754,892...143,767,989
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SOCS1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19910459 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD1 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD2 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
increases expression |
ISO |
Cannabidiol results in increased expression of SOX4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr17:37,615,022...37,619,728
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of SPHK1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr10:105,498,728...105,504,401
Ensembl chr10:105,498,728...105,504,393
|
|
G |
Spic |
Spi-C transcription factor |
increases expression |
ISO |
Cannabidiol results in increased expression of SPIC mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 7:29,225,721...29,233,452
Ensembl chr 7:29,225,727...29,233,392
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression decreases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of SQSTM1 mRNA Cannabidiol results in decreased expression of SQSTM1 protein [Dronabinol co-treated with Cannabidiol] results in decreased expression of SQSTM1 protein; Dronabinol promotes the reaction [Cannabidiol results in decreased expression of SQSTM1 protein] |
CTD |
PMID:21542829 PMID:27769052 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
affects methylation increases expression |
EXP ISO |
Cannabidiol affects the methylation of SRC gene Cannabidiol results in increased expression of SRC mRNA |
CTD |
PMID:30521419 PMID:30742662 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of SRXN1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
St6galnac4 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of ST6GALNAC4 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:11,607,103...11,619,595
Ensembl chr 3:11,607,225...11,619,593
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of STAT1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and results in increased activity of STAT3 protein] |
CTD |
PMID:19910459 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stx11 |
syntaxin 11 |
increases expression |
ISO |
Cannabidiol results in increased expression of STX11 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 1:7,039,160...7,064,870
Ensembl chr 1:7,039,162...7,064,870
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of TAC1 mRNA] |
CTD |
PMID:17672854 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tagap |
T-cell activation RhoGTPase activating protein |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TAGAP mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 1:47,493,990...47,503,492
Ensembl chr 1:47,493,994...47,502,952
|
|
G |
Tbx3 |
T-box transcription factor 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TBX3 gene |
CTD |
PMID:30521419 |
|
NCBI chr12:42,479,518...42,494,588
Ensembl chr12:42,480,560...42,492,526
|
|
G |
Tcf7l1 |
transcription factor 7 like 1 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TCF7L1 gene |
CTD |
PMID:30521419 |
|
NCBI chr 4:100,492,796...100,660,401
Ensembl chr 4:100,491,798...100,660,140
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA] Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TGFB1 mRNA] |
CTD |
PMID:30074247 PMID:32049991 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TGFB3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:109,913,757...109,936,217
Ensembl chr 6:109,913,757...109,935,533
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TGFBR2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Tgif2 |
TGFB-induced factor homeobox 2 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of TGIF2 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 3:152,906,961...152,924,380
Ensembl chr 3:152,909,189...152,924,377
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of TIMP1 mRNA; Cannabidiol results in increased expression of TIMP1 protein ICAM1 mutant form inhibits the reaction [Cannabidiol results in increased expression of TIMP1 protein] |
CTD |
PMID:22198381 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tle1 |
TLE family member 1, transcriptional corepressor |
decreases expression |
ISO |
Cannabidiol results in decreased expression of TLE1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 5:88,546,607...88,630,277
Ensembl chr 5:88,546,568...88,629,491
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of TNF mRNA; Cannabidiol analog inhibits the reaction [Peptidoglycan results in increased expression of TNF protein]; Cannabidiol analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF protein] [Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol analog inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21492165 PMID:30074247 PMID:30742662 PMID:30796934 PMID:31054246 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip2 |
TNF alpha induced protein 2 |
increases expression |
ISO |
Cannabidiol results in increased expression of TNFAIP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 6:135,890,869...135,903,647
Ensembl chr 6:135,890,931...135,903,647
|
|
G |
Tnfrsf18 |
TNF receptor superfamily member 18 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF18 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:173,459,371...173,463,980
Ensembl chr 5:173,460,354...173,463,140
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF9 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:168,009,245...168,035,813
Ensembl chr 5:168,009,393...168,035,810
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tnfsf14 |
TNF superfamily member 14 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF14 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 9:9,761,363...9,765,461
Ensembl chr 9:9,761,536...9,765,186
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TNFSF8 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of TNNT1 mRNA iodoresiniferatoxin inhibits the reaction [Cannabidiol results in increased expression of TNNT1 mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr 1:72,889,270...72,899,629
Ensembl chr 1:72,889,270...72,899,659
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions decreases activity |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]] Cannabidiol metabolite results in decreased activity of TOP2A protein |
CTD |
PMID:29272108 |
|
NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154
|
|
G |
Top2b |
DNA topoisomerase II beta |
multiple interactions decreases activity |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate] Cannabidiol metabolite results in decreased activity of TOP2B protein |
CTD |
PMID:29272108 |
|
NCBI chr15:10,262,972...10,319,741
Ensembl chr15:10,262,651...10,320,233
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
Cannabidiol results in decreased expression of TP53 mRNA |
CTD |
PMID:32553926 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tp53inp1 |
tumor protein p53 inducible nuclear protein 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRP53INP1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 5:24,402,895...24,419,651
Ensembl chr 5:24,410,863...24,416,888
|
|
G |
Tpm3 |
tropomyosin 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TPM3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRAF1 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
affects methylation |
EXP |
Cannabidiol affects the methylation of TRAF3 gene |
CTD |
PMID:30521419 |
|
NCBI chr 6:135,610,698...135,720,247
Ensembl chr 6:135,610,743...135,718,564
|
|
G |
Trat1 |
T cell receptor associated transmembrane adaptor 1 |
increases expression |
ISO |
Cannabidiol results in increased expression of TRAT1 mRNA |
CTD |
PMID:27256343 |
|
NCBI chr11:54,619,169...54,661,284
Ensembl chr11:54,619,129...54,662,353
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of TRIB3 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of TRIB3 mRNA |
CTD |
PMID:21542829 PMID:26504004 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions increases activity |
EXP ISO |
Cannabidiol binds to and results in increased activity of TRPA1 protein Cannabidiol results in increased activity of TRPA1 protein |
CTD |
PMID:18550765 PMID:30074247 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO |
[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; Cannabidiol inhibits the reaction [[Capsaicin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[resiniferatoxin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [Capsaicin binds to TRPV1 protein]; Cannabidiol inhibits the reaction [resiniferatoxin binds to TRPV1 protein]; capsazepine inhibits the reaction [[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; capsazepine inhibits the reaction [Cannabidiol results in increased activity of TRPV1 protein]; TRPV1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] |
CTD |
PMID:11606325 PMID:20668920 PMID:30074247 PMID:31054246 PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
increases activity multiple interactions |
ISO EXP |
Cannabidiol results in increased activity of TRPV2 protein [Cannabidiol results in increased activity of TRPV2 protein] which results in increased uptake of Calcium Cannabidiol analog binds to and results in increased activity of TRPV2 protein; Cannabidiol binds to and results in increased activity of TRPV2 protein |
CTD |
PMID:18550765 PMID:31096838 |
|
NCBI chr10:48,903,540...48,925,036
Ensembl chr10:48,903,540...48,925,030
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] results in increased expression of TSC22D3 mRNA |
CTD |
PMID:26504004 |
|
NCBI chr X:111,884,285...111,944,693
Ensembl chr X:111,884,295...111,887,906
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TUBB2B mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr17:31,441,640...31,444,687
Ensembl chr17:31,441,630...31,482,759
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA]; Cannabidiol results in increased expression of and results in increased activity of TYR protein; SB 203580 inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA] Cannabidiol results in increased expression of TYRP1 mRNA; Cannabidiol results in increased expression of TYRP1 protein |
CTD |
PMID:28601556 |
|
NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ULK1 mRNA] |
CTD |
PMID:30074247 |
|
NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
decreases expression |
ISO |
Cannabidiol results in decreased expression of USP2 mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 8:48,403,985...48,432,525
Ensembl chr 8:48,406,260...48,430,885
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of VEGFA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of VEGFA mRNA |
CTD |
PMID:21542829 PMID:30742662 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vegfb |
vascular endothelial growth factor B |
affects methylation |
EXP |
Cannabidiol affects the methylation of VEGFB gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:222,237,000...222,242,786
Ensembl chr 1:222,239,022...222,242,644
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA] |
CTD |
PMID:32049991 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Vps37b |
VPS37B subunit of ESCRT-I |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of VPS37B mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr12:37,984,790...38,023,369
Ensembl chr12:37,984,790...38,023,368
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
Cannabidiol results in increased expression of VWF mRNA |
CTD |
PMID:21542829 |
|
NCBI chr 4:158,085,059...158,219,525
Ensembl chr 4:158,088,505...158,219,523
|
|
G |
Wasf2 |
WASP family member 2 |
affects methylation |
EXP |
Cannabidiol affects the methylation of WASF2 gene |
CTD |
PMID:30521419 |
|
NCBI chr 5:151,319,382...151,385,051
Ensembl chr 5:151,343,493...151,381,238
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of WNT1 mRNA |
CTD |
PMID:30742662 |
|
NCBI chr 7:140,464,999...140,469,046
Ensembl chr 7:140,464,999...140,469,046
|
|
G |
Wnt11 |
Wnt family member 11 |
affects methylation |
EXP |
Cannabidiol affects the methylation of WNT11 gene |
CTD |
PMID:30521419 |
|
NCBI chr 1:163,794,136...163,813,756
Ensembl chr 1:163,797,660...163,813,756
|
|
G |
Wnt7b |
Wnt family member 7B |
affects methylation |
EXP |
Cannabidiol affects the methylation of WNT7B gene |
CTD |
PMID:30521419 |
|
NCBI chr 7:126,423,418...126,465,724
Ensembl chr 7:126,420,656...126,465,723
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression multiple interactions |
ISO |
Cannabidiol results in increased expression of XBP1 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of XBP1 mRNA |
CTD |
PMID:26504004 PMID:32033040 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
G |
Xcl1 |
X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of XCL1 mRNA] |
CTD |
PMID:27256343 |
|
NCBI chr13:83,199,402...83,202,845
Ensembl chr13:83,199,264...83,202,864
|
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
increases expression |
ISO |
cannabidiolic acid results in increased expression of BHLHE41 mRNA |
CTD |
PMID:25242400 |
|
NCBI chr 4:180,230,742...180,235,138
Ensembl chr 4:180,232,382...180,234,804
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
cannabidiolic acid results in decreased expression of FOS mRNA |
CTD |
PMID:27530354 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases expression |
ISO |
cannabidiolic acid results in increased expression of HTR1A mRNA |
CTD |
PMID:27530354 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression |
ISO |
cannabidiolic acid results in decreased expression of ID1 mRNA |
CTD |
PMID:25242400 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases expression |
ISO |
cannabidiolic acid results in increased expression of PPARG mRNA cannabidiolic acid results in decreased expression of PPARG protein |
CTD |
PMID:28853159 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
cannabidiolic acid results in decreased expression of PTGS2 mRNA cannabidiolic acid inhibits the reaction [GW 501516 results in increased expression of PTGS2 mRNA]; cannabidiolic acid promotes the reaction [GSK0660 results in decreased expression of PTGS2 mRNA] |
CTD |
PMID:25242400 PMID:27530354 PMID:32238697 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity |
ISO |
cannabidiolic acid results in increased activity of TRPA1 protein |
CTD |
PMID:31096838 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpm8 |
transient receptor potential cation channel, subfamily M, member 8 |
decreases expression |
ISO |
cannabidiolic acid results in decreased expression of TRPM8 mRNA |
CTD |
PMID:27530354 |
|
NCBI chr 9:95,393,370...95,484,528
Ensembl chr 9:95,398,237...95,482,890
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
ISO |
cannabidiolic acid results in increased activity of TRPV1 protein [cannabidiolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
multiple interactions increases expression |
ISO |
[cannabidiolic acid results in increased activity of TRPV2 protein] which results in increased uptake of Calcium cannabidiolic acid results in increased expression of TRPV2 mRNA |
CTD |
PMID:27530354 PMID:31096838 |
|
NCBI chr10:48,903,540...48,925,036
Ensembl chr10:48,903,540...48,925,030
|
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases expression |
ISO |
cannabigerol results in increased expression of ADCY5 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases expression |
ISO |
cannabigerol results in decreased expression of ADCY9 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:11,392,698...11,515,406
Ensembl chr10:11,392,625...11,512,600
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression |
ISO |
cannabigerol results in increased expression of AKT1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
cannabigerol results in increased expression of ATF4 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO |
cannabigerol results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
cannabigerol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:33019509 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
cannabigerol results in decreased expression of CASP8 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:22971837 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Clock |
clock circadian regulator |
decreases expression |
ISO |
cannabigerol results in decreased expression of CLOCK mRNA |
CTD |
PMID:33019509 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
cannabigerol affects the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein] |
CTD |
PMID:22971837 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases expression |
ISO |
cannabigerol results in decreased expression of CREB1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
ISO |
cannabigerol results in increased expression of DLGAP1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 9:118,277,046...119,159,807
Ensembl chr 9:118,586,179...119,158,196
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
ISO |
cannabigerol results in decreased expression of DRD2 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
decreases expression |
ISO |
cannabigerol results in decreased expression of EIF2AK3 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
decreases expression |
ISO |
cannabigerol results in decreased expression of ERN1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
increases expression |
ISO |
cannabigerol results in increased expression of GNAI2 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 8:116,370,730...116,391,337
Ensembl chr 8:116,370,744...116,391,307
|
|
G |
Gnal |
G protein subunit alpha L |
decreases expression |
ISO |
cannabigerol results in decreased expression of GNAL mRNA |
CTD |
PMID:33019509 |
|
NCBI chr18:62,805,406...62,946,133
Ensembl chr18:62,805,410...62,944,630
|
|
G |
Gnb4 |
G protein subunit beta 4 |
increases expression |
ISO |
cannabigerol results in increased expression of GNB4 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 2:118,978,965...119,007,877
Ensembl chr 2:118,978,973...119,007,835
|
|
G |
Hap1 |
huntingtin-associated protein 1 |
increases expression |
ISO |
cannabigerol results in increased expression of HAP1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:88,257,975...88,266,210
Ensembl chr10:88,257,976...88,266,210
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:22971837 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:22971837 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
cannabigerol results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Parp4 |
poly (ADP-ribose) polymerase family, member 4 |
decreases expression |
ISO |
cannabigerol results in decreased expression of PARP4 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr15:36,809,362...36,911,167
|
|
G |
Pld1 |
phospholipase D1 |
decreases expression |
ISO |
cannabigerol results in decreased expression of PLD1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 2:113,651,967...113,849,403
Ensembl chr 2:113,652,348...113,849,403
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression increases expression |
ISO |
cannabigerol results in decreased expression of PPARG protein cannabigerol results in increased expression of PPARG mRNA |
CTD |
PMID:28853159 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha |
decreases expression |
ISO |
cannabigerol results in decreased expression of PPP3R1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr14:100,311,224...100,360,879
Ensembl chr14:100,311,173...100,360,879
|
|
G |
Prkca |
protein kinase C, alpha |
increases expression |
ISO |
cannabigerol results in increased expression of PRKCA mRNA |
CTD |
PMID:33019509 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkcb |
protein kinase C, beta |
decreases expression |
ISO |
cannabigerol results in decreased expression of PRKCB mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Shank1 |
SH3 and multiple ankyrin repeat domains 1 |
decreases expression |
ISO |
cannabigerol results in decreased expression of SHANK1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 1:100,297,137...100,344,377
Ensembl chr 1:100,297,152...100,344,377
|
|
G |
Slc18a1 |
solute carrier family 18 member A1 |
decreases expression |
ISO |
cannabigerol results in decreased expression of SLC18A1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr16:22,358,646...22,395,183
Ensembl chr16:22,361,998...22,395,183
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
ISO |
cannabigerol results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc32a1 |
solute carrier family 32 member 1 |
increases expression |
ISO |
cannabigerol results in increased expression of SLC32A1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 3:155,102,980...155,107,815
Ensembl chr 3:155,103,150...155,107,817
|
|
G |
Slc38a1 |
solute carrier family 38, member 1 |
decreases expression |
ISO |
cannabigerol results in decreased expression of SLC38A1 mRNA |
CTD |
PMID:33019509 |
|
NCBI chr 7:137,970,555...138,040,098
Ensembl chr 7:137,975,549...138,039,984
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
cannabigerol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:22971837 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO |
[cannabigerol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases expression |
ISO |
cannabigerolic acid results in increased expression of PPARG mRNA cannabigerolic acid results in decreased expression of PPARG protein |
CTD |
PMID:28853159 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO |
[cannabigerolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein] |
CTD |
PMID:28861508 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein] |
CTD |
PMID:28861508 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
delta(9)-tetrahydrocannabinolic acid results in increased expression of FOSB protein alternative form |
CTD |
PMID:18293355 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of IL6 mRNA] |
CTD |
PMID:28853159 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]] |
CTD |
PMID:28853159 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases expression increases expression |
ISO |
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Rosiglitazone results in increased expression of PPARG mRNA] delta(9)-tetrahydrocannabinolic acid results in decreased expression of PPARG protein delta(9)-tetrahydrocannabinolic acid results in increased expression of PPARG mRNA |
CTD |
PMID:28853159 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
delta(9)-tetrahydrocannabinolic acid results in increased expression of PPARGC1A mRNA |
CTD |
PMID:28853159 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; T 0070907 inhibits the reaction [delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]] |
CTD |
PMID:28853159 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of ARG1 mRNA] |
CTD |
PMID:29560022 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]] |
CTD |
PMID:27611972 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
[HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; HU 308 inhibits the reaction [Glucose results in decreased expression of BECN1 protein]; HU 308 inhibits the reaction [Streptozocin results in decreased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein] |
CTD |
PMID:27611972 PMID:30459625 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] |
CTD |
PMID:27611972 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
EXP |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CD68 protein] |
CTD |
PMID:29560022 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Chi3l3 |
chitinase 3-like 3 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CHI3L3 mRNA] |
CTD |
PMID:29560022 |
|
NCBI chr 2:208,899,871...208,936,858
Ensembl chr 2:208,900,103...208,936,860
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
EXP ISO |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CNR2 mRNA]; HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CNR2 protein] [HU 308 co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of CNR2 mRNA |
CTD |
PMID:29560022 PMID:30232034 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL10 protein] HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL10 mRNA] |
CTD |
PMID:29560022 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL1B mRNA] 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; [HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]]; HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein] |
CTD |
PMID:27611972 PMID:29560022 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL6 mRNA] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL6 protein] |
CTD |
PMID:29560022 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of MRC1 protein] |
CTD |
PMID:29560022 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of MTOR protein] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of MTOR protein]; HU 308 inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein] |
CTD |
PMID:29560022 PMID:30459625 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29560022 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[HU 308 co-treated with Dextran Sulfate] affects the expression of NLRP3 protein |
CTD |
PMID:27611972 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of NOS2 protein] |
CTD |
PMID:29560022 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of PIK3R1 protein] |
CTD |
PMID:29560022 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
HU 308 inhibits the reaction [Glucose results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:30459625 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[HU 308 co-treated with Dextran Sulfate] affects the expression of SQSTM1 protein; HU 308 inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]; HU 308 inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27611972 PMID:30459625 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TGFB1 mRNA] HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TGFB1 protein] |
CTD |
PMID:29560022 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TNF mRNA] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TNF protein] |
CTD |
PMID:29560022 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of N-oleoylethanolamine |
CTD |
PMID:30102254 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases response to substance multiple interactions |
ISO |
PPARA results in increased susceptibility to N-oleoylethanolamine N-oleoylethanolamine binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
N-oleoylethanolamine results in decreased expression of PTGS2 protein |
CTD |
PMID:17906680 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of palmidrol |
CTD |
PMID:30102254 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Apob |
apolipoprotein B |
affects folding |
ISO |
palmidrol affects the folding of APOB protein |
CTD |
PMID:16115474 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
palmidrol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Cldn3 |
claudin 3 |
multiple interactions decreases expression |
ISO |
[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA palmidrol results in decreased expression of CLDN3 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr12:21,831,341...21,832,813
Ensembl chr12:21,831,342...21,832,813
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
palmidrol results in decreased expression of CLDN5 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
[rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:17558434 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects binding multiple interactions |
ISO EXP |
palmidrol binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:10617657 PMID:10688601 PMID:17558434 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of LCN2 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions affects localization |
EXP |
[MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] palmidrol affects the localization of PPARA protein |
CTD |
PMID:17558434 PMID:31787870 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
ISO |
palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of ABCA2 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 3:2,648,787...2,668,770
Ensembl chr 3:2,648,885...2,668,809
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects activity |
ISO |
Win 55212-2 affects the activity of ABCG2 protein |
CTD |
PMID:30083819 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [IL6 protein results in decreased phosphorylation of ACACA protein] |
CTD |
PMID:27324222 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
JTE 907 inhibits the reaction [Win 55212-2 analog results in decreased expression of ACTA2 protein]; Win 55212-2 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Win 55212-2 inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein] |
CTD |
PMID:31901889 PMID:31991773 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases response to substance |
EXP |
ADORA2A protein results in decreased susceptibility to Win 55212-2 |
CTD |
PMID:26526685 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Win 55212-2 results in increased phosphorylation of AKT1 protein CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of AKT1 protein]; Win 55212-2 results in increased phosphorylation of and results in increased activity of AKT1 protein |
CTD |
PMID:12734338 PMID:20619260 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of APAF1 protein |
CTD |
PMID:30776504 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA] |
CTD |
PMID:21350020 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arg1 |
arginase 1 |
multiple interactions affects expression |
ISO |
AM6545 inhibits the reaction [Win 55212-2 affects the expression of ARG1 mRNA] |
CTD |
PMID:30184259 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:12237329 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
GRK2 protein affects the reaction [Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]; Win 55212-2 affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein] |
CTD |
PMID:31024316 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[Win 55212-2 co-treated with CNR2 protein] affects the localization of ARRB2 protein; Win 55212-2 promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 PMID:31901889 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Becn1 |
beclin 1 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of BECN1 protein |
CTD |
PMID:30776504 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp3 |
caspase 3 |
decreases cleavage |
ISO |
Win 55212-2 results in decreased cleavage of CASP3 protein |
CTD |
PMID:30776504 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
decreases cleavage |
ISO |
Win 55212-2 results in decreased cleavage of CASP7 protein |
CTD |
PMID:30776504 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
decreases cleavage |
ISO |
Win 55212-2 results in decreased cleavage of CASP8 protein |
CTD |
PMID:30776504 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
AM 281 inhibits the reaction [Win 55212-2 results in increased activity of CASP9 protein] |
CTD |
PMID:28495606 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of CCT7 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 4:117,235,023...117,252,265
Ensembl chr 4:117,235,023...117,252,265
|
|
G |
Cdk14 |
cyclin-dependent kinase 14 |
increases expression |
ISO |
Win 55212-2 results in increased expression of CDK14 mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 4:25,825,567...26,419,443
Ensembl chr 4:25,825,567...26,419,127
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
increases expression |
ISO |
Win 55212-2 results in increased expression of CITED2 mRNA; Win 55212-2 results in increased expression of CITED2 protein |
CTD |
PMID:12237329 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[Win 55212-2 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein |
CTD |
PMID:27920472 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases response to substance affects response to substance decreases expression affects localization increases activity affects binding |
ISO EXP |
CNR1 affects the reaction [Win 55212-2 results in increased activity of MAPK1 protein]; CNR1 affects the reaction [Win 55212-2 results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [Win 55212-2 results in increased activity of CNR1]; Rimonabant inhibits the reaction [Win 55212-2 results in increased activity of CNR1]; Win 55212-2 affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; Win 55212-2 binds to and results in increased activity of CNR1 protein; Win 55212-2 inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; Win 55212-2 promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] CNR1 protein results in increased susceptibility to Win 55212-2 CNR1 protein mutant form affects the susceptibility to Win 55212-2 Win 55212-2 results in decreased expression of CNR1 mRNA; Win 55212-2 results in decreased expression of CNR1 protein Win 55212-2 affects the localization of CNR1 protein [Rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to Win 55212-2; [Win 55212-2 binds to and results in increased activity of CNR1 protein] affects the reaction [Potassium Chloride results in increased transport of Calcium]; AM 251 inhibits the reaction [Win 55212-2 results in decreased expression of CNR1 mRNA]; AM 251 inhibits the reaction [Win 55212-2 results in decreased expression of CNR1 protein]; CNR1 protein affects the reaction [Win 55212-2 inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[Win 55212-2 binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Win 55212-2 binds to and results in increased activity of CNR1 protein [Win 55212-2 binds to and results in increased activity of CNR1 protein] which results in increased expression of FOS protein; CNRIP1 protein inhibits the reaction [Win 55212-2 affects the localization of CNR1 protein]; Win 55212-2 binds to and results in increased activity of CNR1 protein Win 55212-2 results in increased activity of CNR1; Win 55212-2 results in increased activity of CNR1 protein Win 55212-2 binds to CNR1 protein |
CTD |
PMID:8526880 PMID:10871313 PMID:12421626 PMID:12560108 PMID:16157695 PMID:16438957 PMID:17572696 PMID:21281698 PMID:22044209 PMID:22971837 PMID:27513693 PMID:29113897 PMID:29730318 PMID:29883990 PMID:30165669 PMID:30629988 PMID:31024316 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects response to substance increases activity multiple interactions affects binding |
ISO EXP |
CNR2 gene SNP affects the susceptibility to Win 55212-2 Win 55212-2 results in increased activity of CNR2 protein [Win 55212-2 co-treated with CNR2 protein] affects the localization of ARRB2 protein; GRK2 protein affects the reaction [Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]; ridaifen-B inhibits the reaction [Win 55212-2 binds to and results in increased activity of CNR2 protein]; Win 55212-2 binds to and results in increased activity of CNR2 protein; Win 55212-2 inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; Win 55212-2 promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] Win 55212-2 binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to Win 55212-2; CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of AKT1 protein]; CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR2 protein affects the reaction [Win 55212-2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Win 55212-2 binds to and results in increased activity of CNR2 protein |
CTD |
PMID:10688601 PMID:12734338 PMID:17572696 PMID:20124950 PMID:21281698 PMID:21871882 PMID:22044209 PMID:22971837 PMID:29883990 PMID:29906493 PMID:31024316 PMID:31901889 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
multiple interactions |
ISO |
CNRIP1 protein inhibits the reaction [Win 55212-2 affects the localization of CNR1 protein] |
CTD |
PMID:27513693 |
|
NCBI chr14:100,217,547...100,247,235
Ensembl chr14:100,217,289...100,247,235
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Win 55212-2 results in increased expression of CTSD protein |
CTD |
PMID:30776504 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Win 55212-2 results in increased expression of DDIT3 mRNA]; methyl-beta-cyclodextrin inhibits the reaction [Win 55212-2 results in increased expression of DDIT3 mRNA] |
CTD |
PMID:30502353 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Efs |
embryonal Fyn-associated substrate |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of EFS mRNA |
CTD |
PMID:12237329 |
|
NCBI chr15:33,579,952...33,590,217
Ensembl chr15:33,578,381...33,589,522
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
RTKI cpd inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20619260 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
decreases expression |
ISO |
Win 55212-2 results in decreased expression of EIF4B mRNA |
CTD |
PMID:12237329 |
|
NCBI chr 7:143,679,656...143,701,452
Ensembl chr 7:143,679,617...143,701,452
|
|
G |
Eno2 |
enolase 2 |
decreases expression multiple interactions |
ISO |
Win 55212-2 results in decreased expression of ENO2 protein Win 55212-2 inhibits the reaction [IL6 protein results in increased expression of ENO2 protein] |
CTD |
PMID:27324222 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; Win 55212-2 inhibits the reaction [IL1B protein results in increased expression of F3 mRNA] |
CTD |
PMID:27556861 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions affects expression |
ISO EXP |
[Acetaminophen co-treated with Win 55212-2] results in decreased expression of FAAH mRNA Win 55212-2 affects the expression of FAAH mRNA [Win 55212-2 co-treated with Rimonabant] affects the expression of FAAH mRNA |
CTD |
PMID:30165669 PMID:32833042 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
multiple interactions |
ISO |
[Acetaminophen co-treated with Win 55212-2] results in decreased expression of FAAH mRNA |
CTD |
PMID:30165669 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Win 55212-2 binds to and results in increased activity of CNR1 protein] which results in increased expression of FOS protein |
CTD |
PMID:12560108 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gck |
glucokinase |
increases expression |
ISO |
Win 55212-2 results in increased expression of GCK mRNA; Win 55212-2 results in increased expression of GCK protein |
CTD |
PMID:12237329 |
|
NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
Win 55212-2 inhibits the reaction [amyloid beta-protein (25-35) affects the localization of GJA1 protein] |
CTD |
PMID:27757991 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gphn |
gephyrin |
multiple interactions |
EXP |
Win 55212-2 promotes the reaction [Cocaine results in increased phosphorylation of GPHN protein] |
CTD |
PMID:32312805 |
|
NCBI chr 6:101,327,874...101,859,169
Ensembl chr 6:101,532,518...101,859,164
|
|
G |
Gpr55 |
G protein-coupled receptor 55 |
affects response to substance |
ISO |
GPR55 protein affects the susceptibility to Win 55212-2 |
CTD |
PMID:31877572 |
|
NCBI chr 9:92,961,431...93,011,157
Ensembl chr 9:92,962,738...92,963,697
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
EXP |
Win 55212-2 results in decreased expression of GRIA1 protein |
CTD |
PMID:32312805 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
decreases expression |
EXP |
Win 55212-2 results in decreased expression of GRIA2 protein |
|